An ampoule with BNT162b2, the mRNA-based vaccine candidate against Covid-19, produced by BioNTech, Pfizer’s German partner. The company has said its candidate has proved 90 per cent effective in preventing symptomatic infection. Photo: EPA-EFE An ampoule with BNT162b2, the mRNA-based vaccine candidate against Covid-19, produced by BioNTech, Pfizer’s German partner. The company has said its candidate has proved 90 per cent effective in preventing symptomatic infection. Photo: EPA-EFE
An ampoule with BNT162b2, the mRNA-based vaccine candidate against Covid-19, produced by BioNTech, Pfizer’s German partner. The company has said its candidate has proved 90 per cent effective in preventing symptomatic infection. Photo: EPA-EFE

Letters | As Hong Kong awaits the coronavirus vaccine, it must fine-tune its distribution plan

  • Initial supplies of the Covid-19 vaccine will be limited, so public health authorities must use this time to come up with plans on how to distribute it, which groups will receive priority and how to overcome people’s reluctance to being vaccinated

Topic |   Coronavirus pandemic
An ampoule with BNT162b2, the mRNA-based vaccine candidate against Covid-19, produced by BioNTech, Pfizer’s German partner. The company has said its candidate has proved 90 per cent effective in preventing symptomatic infection. Photo: EPA-EFE An ampoule with BNT162b2, the mRNA-based vaccine candidate against Covid-19, produced by BioNTech, Pfizer’s German partner. The company has said its candidate has proved 90 per cent effective in preventing symptomatic infection. Photo: EPA-EFE
An ampoule with BNT162b2, the mRNA-based vaccine candidate against Covid-19, produced by BioNTech, Pfizer’s German partner. The company has said its candidate has proved 90 per cent effective in preventing symptomatic infection. Photo: EPA-EFE
READ FULL ARTICLE